-
New MS Therapy Company to Focus on Rejuvenating Coating That Protects Nerve Cells
A new company called Pipeline Therapeutics will focus on developing next-generation therapies for regenerating the key nerve-protection process that is damaged in multiple sclerosis.
Roche, Inception Sciences, and the venture capital firm Versant Ventures laid the groundwork for Pipeline by establishing a partnership in June 2014 that formed the Inception 5 program. Its goal was to develop therapies for remyelination — the process of repairing the myelin coating that protects nerve fibers. Myelin damage is a hallmark of MS.
The early promise of the remyelination therapy development program has led to Pipeline Therapeutics being formed to take over the Inception 5 effort.
Versant supported Inception 5 with financing. Roche provided research funding in exchange for an option to acquire a therapy program that could achieve investigational new drug status. The U.S. Food and Drug Administration awards the status so that companies can market an experimental therapy across state lines.
Read more about this news here: “New MS Therapy Company, Pipeline, to Focus on Rejuvenating Coating That Protects Nerve Cells“
-
0 Replies
Sorry, there were no replies found.
Log in to reply.